This company is an established ambulatory infusion provider with a long operating history and a multi-state network of outpatient infusion centers. Supported by an in-house licensed pharmacy and a centralized billing and reimbursement team, it administers more than 20,000 patient infusions a year- predominately long -term biologic therapies for chronic and rare diseases at a lower cost, close to home alternative to hospital outpatient infusion. The business has a 95 % recurring revenue. Clinical leadership and a tenured management team are expected to remain in place after the transaction.